

Report of Organizational Actions Affecting Basis of Securities

▶ See separate instructions.

Part I Reporting Issuer			
1 Issuer's name Chinook Therapeutics U.S., Inc.		2 Issuer's employer identification number (EIN) 83-2535029	
3 Name of contact for additional information Kirk Schumacher	4 Telephone No. of contact 206-321-4031	5 Email address of contact kschumacher@chinooktx.com	
6 Number and street (or P.O. box if mail is not delivered to street address) of contact 1600 Fairview Avenue East, Suite 100		7 City, town, or post office, state, and ZIP code of contact Seattle, WA 98102	
8 Date of action October 2, 2020		9 Classification and description Common Stock	
10 CUSIP number N/A	11 Serial number(s) N/A	12 Ticker symbol N/A	13 Account number(s) N/A

Part II Organizational Action Attach additional statements if needed. See back of form for additional questions.

14 Describe the organizational action and, if applicable, the date of the action or the date against which shareholders' ownership is measured for the action ▶ On October 1, 2020, the stockholders of Aduro Biotech, Inc. approved the merger with Chinook Therapeutics U.S., Inc. which was effective on October 5, 2020 and pursuant to which Chinook Therapeutics U.S., Inc. became a wholly owned subsidiary of Aduro Biotech, Inc. and the surviving corporation of the merger.

15 Describe the quantitative effect of the organizational action on the basis of the security in the hands of a U.S. taxpayer as an adjustment per share or as a percentage of old basis ▶ Pursuant to the terms of a merger agreement, Aduro Biotech, Inc. issued shares of its common stock to the stockholders of Chinook Therapeutics U.S. Inc., at an exchange ratio of 0.292188 shares of Aduro common stock for each share of Chinook Therapeutics U.S. Inc. capital stock outstanding immediately prior to the merger. No fractional shares of Aduro common stock were issued in connection with the merger. Any fractional shares of Aduro common stock resulting from the conversion of Chinook capital stock into the right to receive a number of Aduro common stock equal to the exchange ratio or from the settlement of Chinook options pursuant to the Merger Agreement (after aggregating all fractional shares of Aduro common stock issuable to such holder) rounded down to the nearest whole share of Aduro common stock, with no cash being paid for any fractional share of Aduro common stock eliminated by such rounding.

16 Describe the calculation of the change in basis and the data that supports the calculation, such as the market values of securities and the valuation dates ▶ Each share of Chinook Therapeutics U.S. Inc. common stock was converted into 0.292188 of Aduro Biotech, Inc. common shares. The exercise price of Chinook Therapeutics U.S. Inc. stock options was increased by a factor of 3.42.

No fractional shares of Aduro common stock were issued in connection with the merger. Any fractional shares of Aduro common stock resulting from the conversion of Chinook capital stock into the right to receive a number of Aduro common stock equal to the exchange ratio or from the settlement of Chinook options pursuant to the Merger Agreement (after aggregating all fractional shares of Aduro common stock issuable to such holder) rounded down to the nearest whole share of Aduro common stock, with no cash being paid for any fractional share of Aduro common stock eliminated by such rounding.

Part II Organizational Action (continued)

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶

IRC section 368, 354, 358, 1001, and 1012

18 Can any resulting loss be recognized? ▶ N/A

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ The reportable tax year is the calendar year ending December 31, 2020

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Sign Here

Signature ▶ *Tom Swallow*

Date ▶ November 18, 2020

Print your name ▶ Tom Swallow

Title ▶ VP, Finance

Paid Preparer Use Only

Print/Type preparer's name	Preparer's signature	Date	Check <input type="checkbox"/> if self-employed	PTIN
Firm's name ▶			Firm's EIN ▶	
Firm's address ▶			Phone no.	